Pyrrolopyridine Crystal Forms Balancing Stability and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pyrrolopyridine derivatives face issues with low solubility and bioavailability due to crystalline forms, and amorphous forms are unstable, leading to difficulties in drug release and blood concentration control.
Innovation Solution
Development of crystalline forms A, B, C, and D of pyrrolopyridine derivatives, characterized by specific X-ray diffraction patterns and DSC endothermic transition peaks, produced through solvent-based methods, including stirring and drying processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If crystalline form is used for pyrrolopyridine derivative, then stability is improved, but solubility and bioavailability deteriorate
Solution Approach 1:
The patent applies parameter changes by discovering and characterizing multiple crystalline forms (Form A, B, C, D) with different physical properties through controlled crystallization processes. Each form exhibits distinct melting points, X-ray diffraction patterns, and solubility characteristics, allowing optimization of both stability and bioavailability by selecting appropriate crystalline forms for specific pharmaceutical applications
Solution Approach 2:
The patent utilizes phase transitions through differential scanning calorimetry (DSC) to identify and characterize crystalline forms by detecting endothermic transition peaks. The phase change from amorphous to crystalline state is harnessed to achieve stable pharmaceutical formulations while maintaining acceptable solubility profiles through careful control of crystallization conditions
2Quantity of substance
If amorphous form is used for pyrrolopyridine derivative, then solubility is improved, but stability deteriorates
Solution Approach 1:
The patent employs parameter changes by systematically varying crystallization conditions (solvent type, temperature, pH) to transform amorphous forms into stable crystalline forms. This transformation maintains solubility while significantly improving stability, as demonstrated by the consistent performance of crystalline forms A-D in pharmaceutical formulations
3Stability of the object's composition
If crystalline form is used for pyrrolopyridine derivative, then stability is improved, but bioavailability deteriorates
Solution Approach 1:
The patent leverages phase transitions and polymorphic forms to optimize bioavailability while maintaining stability. By identifying crystalline forms with specific melting points and solubility characteristics, the patent achieves formulations that maintain drug stability during storage while ensuring adequate bioavailability through controlled release and dissolution properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms exhibit low hygroscopicity, stability, and improved solubility, ensuring stable pharmaceutical formulations and high bioavailability.
Implementation Method 1
which has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2Θ±0.2°) of 9.26°, 10.47°, 12.76°, 14.70°, 15.83°, and 16.61°
Implementation Method 2
the crystalline form A may have a differential scanning calorimetry (DSC) endothermic transition peak at 208 to 215 °C when the heating rate is 10 °C/min
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention pertains to: a polymorph of a pyrrolopyridine derivative which is a non-catalytic site integrase inhibitor; and a method for producing same. The novel polymorph of the present invention exhibits excellent non-hygroscopicity and stability and is thus suitable for pharmaceutical preparations.